PRODUCTS

PRODUCTS

position:Home > PRODUCTS > Genetic testing and personalized medication evaluation for hereditary early-onset coronary heart disease

Genetic testing and personalized medication evaluation for hereditary early-onset coronary heart disease

Contact Us

Product Introduction

Genetic testing for hereditary early-onset coronary heart disease and individualized medication evaluation is a genetic testing product based on Cygnus sequencer's S100 gene sequencer. It mainly detects genes associated with the risk of early-onset coronary heart disease, including LDLR, LDLRAP1, PCSK9, ABCG5, ABCG8, and APOB. This product is helpful for the early detection and prevention of the disease. Additionally, it also analyzes statin-related genes to evaluate the risk of adverse reactions and the effectiveness of statin drugs

Product Features

Convenient and flexible

Authoritative and efficient

Sensitive and accurate

Applicable people

People with early-onset coronary heart disease and other cardiovascular diseases

People with a family history of early-onset coronary heart disease or imaging evidence of atherosclerosis

People with hypertension, hyperglycemia and hyperlipidemia (adult serum LDL-C ≥ 4.1 mmol/L)

People whose first-degree relatives have any one or all of the above three conditions

People with hypercholesterolemia and sitosterolemia

People concerned about cardiovascular health

Clinical significance

clinical significance

indicates genetic risk

statin medication guidance

health screening

risk assessment

Detection Process

DNA extraction

quality control

library preparation

library quality control

sequencing

data analysis

report review

report release

Lead time

7 working days after receiving qualified samples.